Among non-HRRm castrate resistant prostate cancer patients, are there features predictive of response to PROPEL regimen of abiraterone/olaparib?

There is a theory that abiraterone can lead to changes in the tumor that could make it susceptible to PARP inhibitors. I understand that the clinical trial suggests that this may be the case, but I think we need more information as to whether or not this is actually happening.

This is a very important question as well which remains unanswered. Currently, there are many validated clinical features that can prognosticate outcomes in the first line mCRPC setting during potent AR therapy. See: Armstrong et al., PMID 32527692. Examples include patterns of metastatic spread, LD...

The overall effect is that radiographic PFS improved for patients treated with combination of abiraterone/Olaparib regardless of HRR status. The PFS improvement holds for the non-HRRm population and I have not seen other analyses within the non-HRRm population that predicts for benefit. My suspicion...